Breaking News Instant updates and real-time market news.

2022-04-21 08:55:40 MBRX Moleculin Biotech $1.92 / + (+0.00%) 08:55 04/21/22 04/21 08:55 04/21/22 08:55	Moleculin Biotech receives IND clearance for Phase 1 study of glioma candidate Moleculin Biotech announced that the FDA is allowing the company's Investigational New Drug application to study WP1066 for the treatment of recurrent malignant glioma. With this IND now cleared, Moleculin plans to evaluate strategic partnerships and collaborations to conduct a Phase 1 open label, single arm, dose escalation study of the safety, pharmacokinetics and efficacy of oral WP1066 in adult patients with recurrent malignant glioma. WP1066 is the company's flagship Immune/Transcription Modulator designed to stimulate the immune response to tumors by inhibiting the errant activity of Regulatory T-Cells while also inhibiting key oncogenic transcription factors. These transcription factors are widely sought targets that are believed to contribute to an increase in cell survival and proliferation. WP1066 is currently being evaluated for the treatment of pediatric brain tumors. The company has received Orphan Drug Designation for WP1066 for the treatment of brain tumors, as well as Rare Pediatric Disease designation for three other pediatric indications. Additionally, WP1066 + radiation is being evaluated, pre-clinically, in the treatment of Glioblastoma Multiforme. Glioma is a common type of tumor originating in the brain. About 33% of all brain tumors are gliomas.	26 May

2022-04-21 08:55:40

MBRX

Moleculin Biotech

$1.92 / + (+0.00%)

08:55

04/21/22

04/21

08:55

04/21/22

08:55

Moleculin Biotech receives IND clearance for Phase 1 study of glioma candidate

Moleculin Biotech announced that the FDA is allowing the company's Investigational New Drug application to study WP1066 for the treatment of recurrent malignant glioma. With this IND now cleared, Moleculin plans to evaluate strategic partnerships and collaborations to conduct a Phase 1 open label, single arm, dose escalation study of the safety, pharmacokinetics and efficacy of oral WP1066 in adult patients with recurrent malignant glioma. WP1066 is the company's flagship Immune/Transcription Modulator designed to stimulate the immune response to tumors by inhibiting the errant activity of Regulatory T-Cells while also inhibiting key oncogenic transcription factors. These transcription factors are widely sought targets that are believed to contribute to an increase in cell survival and proliferation. WP1066 is currently being evaluated for the treatment of pediatric brain tumors. The company has received Orphan Drug Designation for WP1066 for the treatment of brain tumors, as well as Rare Pediatric Disease designation for three other pediatric indications. Additionally, WP1066 + radiation is being evaluated, pre-clinically, in the treatment of Glioblastoma Multiforme. Glioma is a common type of tumor originating in the brain. About 33% of all brain tumors are gliomas.

26
May

OTHER BREAKING NEWS FROM THE FLY

Periodicals	Microsoft says Xbox One sold less than half as many units as PS4, Verge says » 12:03 08/15/22 08/15 12:03 08/15/22 12:03 MSFT Microsoft $292.47 / +0.6 (+0.21%) , SONY Sony $86.95 / +0.195 (+0.22%) , ATVI Activision Blizzard $80.53 / -0.22 (-0.27%) Microsoft (MSFT) told… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options MSFT SONY ATVI MSFT Microsoft $292.47 / +0.6 (+0.21%) 08/12/22 Warner Bros. Discovery's 'Hogwarts Legacy' game out February 10, 2023 08/09/22 Barclays deploys Microsoft teams as collaboration platform 08/08/22 Take-Two delays 'Marvel's Midnight Suns' to fiscal 2023 08/04/22 Atlassian names Microsoft's Joe Binz as new CFO SONY Sony $86.95 / +0.195 (+0.22%) 08/12/22 Warner Bros. Discovery's 'Hogwarts Legacy' game out February 10, 2023 08/08/22 Take-Two delays 'Marvel's Midnight Suns' to fiscal 2023 08/07/22 Fly Intel: Top five weekend stock stories 08/02/22 U.S. video game consumer spending fell 13% y/y in Q2, says NPD ATVI Activision Blizzard $80.53 / -0.22 (-0.27%) 08/02/22 U.S. video game consumer spending fell 13% y/y in Q2, says NPD 07/25/22 NetEase launches Diablo Immortal in Chinese market on Android, iOS 07/21/22 Activision Blizzard workers stage walkout to 'end gender inequity' 07/15/22 Bandai Namco's 'Elden Ring' best selling game in U.S. in June, says NPD MSFT SONY ATVI MSFT Microsoft $292.47 / +0.6 (+0.21%) 08/11/22 Guggenheim Microsoft initiated with a Neutral at Guggenheim 08/08/22 B. Riley B. Riley thinks Globalstar's mystery satellite capacity customer is Apple 08/04/22 MKM Partners 8x8 initiated with a Neutral at MKM Partners 08/04/22 Deutsche Bank Activision Blizzard price target lowered to $84 from $95 at Deutsche Bank SONY Sony $86.95 / +0.195 (+0.22%) 07/08/22 Macquarie Sony upgraded to Outperform, added to 'Marquee Buy' list at Macquarie 07/05/22 Citi Sony downgraded to Neutral from Buy at Citi 05/18/22 Oppenheimer Sony price target lowered to $125 from $150 at Oppenheimer 04/13/22 CLSA Sony downgraded to Outperform from Buy at CLSA ATVI Activision Blizzard $80.53 / -0.22 (-0.27%) 08/04/22 Deutsche Bank Activision Blizzard price target lowered to $84 from $95 at Deutsche Bank 07/25/22 MoffettNathanson Activision Blizzard upgraded to Outperform at MoffettNathanson 05/31/22 Benchmark Marcus, Imax, WWE added to entertainment top ideas list at Benchmark 05/06/22 Benchmark Playstudios could still be target as industry consolidates, says Benchmark MSFT SONY ATVI MSFT Microsoft $292.47 / +0.6 (+0.21%) 07/26/22 Microsoft sees FY23 revenue growth in double digits, consensus $225.98B 07/26/22 Microsoft reports Q4 EPS $2.23, consensus $2.30 07/26/22 Notable companies reporting after market close 06/02/22 Microsoft lowers Q4 EPS view to $2.24-$2.32 from $2.28-$2.35, consensus $2.33 SONY Sony $86.95 / +0.195 (+0.22%) 07/29/22 Sony raises FY22 consolidated sales view Y11.5T from Y11.4T 07/29/22 Sony reports Q1 revenue Y2.31T vs. Y2.26T last year 05/10/22 Sony sees FY22 consolidated sales Y11.4T vs. Y9.921B in FY21 05/10/22 Sony reports FY21 revenue Y9.921B vs. Y8.998B last year ATVI Activision Blizzard $80.53 / -0.22 (-0.27%) 08/01/22 Activision Blizzard reports Q2 adjusted EPS 48c, consensus 48c 08/01/22 Notable companies reporting after market close 04/25/22 Activision Blizzard reports Q1 EPS 64c, consensus 70c MSFT SONY ATVI MSFT Microsoft $292.47 / +0.6 (+0.21%) 11:48 Today Sony's 'Horizon Forbidden West' still top seller in U.K., Gamesindustry.biz says 08/11/22 Game console sales fall 16% m/m in the U.K. in July, Gamesindustry.biz reports 08/11/22 Microsoft claims Sony pays developers to not put games on Game Pass, VGC says 08/10/22 Microsoft dismisses Sony claim that Activision deal is anticompetitive, VGC says SONY Sony $86.95 / +0.195 (+0.22%) 11:48 Today Sony's 'Horizon Forbidden West' still top seller in U.K., Gamesindustry.biz says 08/11/22 Game console sales fall 16% m/m in the U.K. in July, Gamesindustry.biz reports 08/11/22 Microsoft claims Sony pays developers to not put games on Game Pass, VGC says 08/10/22 Microsoft dismisses Sony claim that Activision deal is anticompetitive, VGC says ATVI Activision Blizzard $80.53 / -0.22 (-0.27%) 08/11/22 Microsoft claims Sony pays developers to not put games on Game Pass, VGC says 08/10/22 Microsoft dismisses Sony claim that Activision deal is anticompetitive, VGC says 08/03/22 Activision Blizzard, NetEase drop Warcraft mobile game, Bloomberg says 08/01/22 Sony says Microsoft owning 'Call of Duty' could affect console choice, VGC says MSFT SONY ATVI MSFT Microsoft $292.47 / +0.6 (+0.21%) 08/12/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/09/22 What You Missed On Wall Street On Tuesday 08/09/22 What You Missed This Week in Video Games 08/02/22 What You Missed This Week in Video Games SONY Sony $86.95 / +0.195 (+0.22%) 08/09/22 What You Missed This Week in Video Games 08/07/22 Box Office Battle: ‘Bullet Train’ wins weekend with $30.1M debut 08/02/22 What You Missed This Week in Video Games 07/31/22 Box Office Battle: ‘DC League of Super-Pets’ wins weekend with $23M debut ATVI Activision Blizzard $80.53 / -0.22 (-0.27%) 08/09/22 What You Missed This Week in Video Games 08/02/22 What You Missed On Wall Street On Tuesday 08/02/22 What You Missed This Week in Video Games 08/02/22 What You Missed On Wall Street This Morning MSFT ATVI MSFT Microsoft $292.47 / +0.6 (+0.21%) 07/28/22 Notable open interest changes for July 28th 07/26/22 Microsoft options imply 4.7% move in share price post-earnings 06/03/22 Unusually active option classes on open June 3rd 06/02/22 Unusually active option classes on open June 2nd ATVI Activision Blizzard $80.53 / -0.22 (-0.27%) 08/09/22 Activision Blizzard put volume heavy and directionally bearish 08/01/22 Activision Blizzard options imply 2.6% move in share price post-earnings 05/02/22 Unusually active option classes on open May 2nd 04/25/22 Unusually active option classes on open April 25th
Hot Stocks	Holland America Line simplifies COVID-19 procedures » 12:03 08/15/22 08/15 12:03 08/15/22 12:03 CCL Carnival $10.75 / +0.04 (+0.37%) , CUK Carnival plc $9.79 / +0.04 (+0.41%) Holland America Line is… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Options CCL CUK CCL Carnival $10.75 / +0.04 (+0.37%) 08/12/22 Carnival removes pre-cruise testing for vaccinate guests 08/04/22 Carnival upgrading global fleet with fuel- and energy-saving technology 08/01/22 Carnival welcomes 3M guests since restart of guest operations in July 2021 07/21/22 Carnival falls -11.8% CUK Carnival plc $9.79 / +0.04 (+0.41%) 08/04/22 Carnival upgrading global fleet with fuel- and energy-saving technology 08/01/22 Carnival welcomes 3M guests since restart of guest operations in July 2021 07/21/22 Carnival plc falls -12.3% 07/21/22 Carnival plc falls -10.6% CCL CUK CCL Carnival $10.75 / +0.04 (+0.37%) 07/22/22 Truist Carnival price target lowered to $8 from $15 at Truist 07/21/22 Stifel Carnival selloff 'coming for sure' as equity raise will cause panic, says Stifel 07/04/22 HSBC HSBC says too early to call inflection point for Carnival 06/29/22 Morgan Stanley Morgan Stanley cuts Carnival price target to $7, sees bear case of zero CUK Carnival plc $9.79 / +0.04 (+0.41%) 08/10/22 UBS Carnival plc price target raised to 884 GBp from 878 GBp at UBS 07/21/22 Stifel Carnival selloff 'coming for sure' as equity raise will cause panic, says Stifel 06/29/22 Morgan Stanley Morgan Stanley cuts Carnival price target to $7, sees bear case of zero 04/04/22 UBS Carnival plc price target raised to 1,537 GBp from 1,422 GBp at UBS CCL CCL Carnival $10.75 / +0.04 (+0.37%) 06/24/22 Carnival expects a net loss for Q3 06/24/22 Carnival reports Q2 EPS ($1.61), consensus ($1.08) 06/23/22 Notable companies reporting before tomorrow's open 06/23/22 Notable companies reporting before tomorrow's open 21 Jul CCL CCL Carnival $10.75 / +0.04 (+0.37%) 07/02/22 Not the time to bottom-fish cruise operator stocks, Barron's says 06/13/22 Carnival CEO tells Bloomberg company is 'recession resilient' 05/24/22 Carnival in talks to sell Seabourn to Saudi fund, CNBC's Mody reports 03/02/22 Carnival, Norwegian update mask policy, now optional for most, WSJ reports CCL CCL Carnival $10.75 / +0.04 (+0.37%) 08/05/22 Sell these stocks now, proven algorithm says 07/22/22 Sell these stocks now, proven algorithm says 07/21/22 What You Missed On Wall Street On Thursday 07/21/22 What You Missed On Wall Street This Morning CCL CCL Carnival $10.75 / +0.04 (+0.37%) 08/10/22 Early notable gainers among liquid option names on August 10th 07/29/22 Carnival call volume above normal and directionally bullish 07/19/22 Early notable gainers among liquid option names on July 19th 07/18/22 Early notable gainers among liquid option names on July 18th
Initiation	Haleon initiated with a Sector Perform at RBC Capital » 12:01 08/15/22 08/15 12:01 08/15/22 12:01 HLN Haleon $6.35 / -0.345 (-5.15%) , PFE Pfizer $49.55 / -0.55 (-1.10%) , GSK GSK plc $34.55 / -1.495 (-4.15%) RBC Capital analyst James… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options HLN PFE GSK HLN Haleon $6.35 / -0.345 (-5.15%) 08/11/22 Haleon says it is not a party to any Zantac claims 08/11/22 GSK says no new 'material developments' related to Zantac litigation 07/18/22 GSK plc announces completion of demerger of Haleon PFE Pfizer $49.55 / -0.55 (-1.10%) 09:31 Today Pfizer Chairman, CEO Bourla tests positive for COVID-19 08/12/22 Pfizer reports 'positive' results from Phase 3 study of 20vPnC 08/11/22 Haleon says it is not a party to any Zantac claims 08/11/22 Sanofi says 'confident in its legal defenses' related to U.S. Zantac litigation GSK GSK plc $34.55 / -1.495 (-4.15%) 09:49 Today Ideaya Biosciences down 34% after GSK waived option on IDE397 08/11/22 Haleon says it is not a party to any Zantac claims 08/11/22 GSK says no new 'material developments' related to Zantac litigation 08/11/22 Sanofi says 'confident in its legal defenses' related to U.S. Zantac litigation HLN PFE GSK HLN Haleon $6.35 / -0.345 (-5.15%) 08/12/22 JPMorgan Sanofi may not be liable for any Zantac litigation damages, says JPMorgan 08/11/22 JPMorgan Perrigo, Pfizer appear to have manageable Zantac exposure, says JPMorgan 08/11/22 Deutsche Bank Zantac cases likely a short-term headwind for GSK, Sanofi, says Deutsche Bank 07/29/22 Deutsche Bank Haleon initiated with a Hold at Deutsche Bank PFE Pfizer $49.55 / -0.55 (-1.10%) 08/14/22 BofA Pfizer Prevnar-20 miss on co-primary endpoint could help Vaxcyte, says BofA 08/12/22 JPMorgan Sanofi may not be liable for any Zantac litigation damages, says JPMorgan 08/11/22 JPMorgan Perrigo, Pfizer appear to have manageable Zantac exposure, says JPMorgan 08/11/22 Deutsche Bank Zantac cases likely a short-term headwind for GSK, Sanofi, says Deutsche Bank GSK GSK plc $34.55 / -1.495 (-4.15%) 10:20 Today Stifel Ideaya Biosciences downgraded to Hold at Stifel after GSK waives IDE397 opt-in 08/12/22 JPMorgan Sanofi may not be liable for any Zantac litigation damages, says JPMorgan 08/11/22 JPMorgan Perrigo, Pfizer appear to have manageable Zantac exposure, says JPMorgan 08/11/22 Deutsche Bank Zantac cases likely a short-term headwind for GSK, Sanofi, says Deutsche Bank PFE GSK PFE Pfizer $49.55 / -0.55 (-1.10%) 07/28/22 Pfizer raises FY22 adjusted EPS view to $6.30-$6.45 from $6.25-$6.45 07/28/22 Pfizer reports Q2 adjusted EPS $2.04, consensus $1.80 07/27/22 Notable companies reporting before tomorrow's open 07/27/22 Notable companies reporting before tomorrow's open GSK GSK plc $34.55 / -1.495 (-4.15%) 07/27/22 GSK plc reports Q2 adjusted EPS 34.7p vs. 28.2p last year 04/27/22 GlaxoSmithKline reaffirms FY22 sales growth between 5%-7% at CER 04/27/22 GlaxoSmithKline reports Q1 adjusted EPS 32.8p vs. 22.9p last year 04/13/22 GlaxoSmithKline backs FY22 revenue view up 5%-7% at CER, consensus $47.34B HLN PFE GSK HLN Haleon $6.35 / -0.345 (-5.15%) 08/11/22 GSK, Sanofi weakness related to Zantac litigation worries, Bloomberg reports PFE Pfizer $49.55 / -0.55 (-1.10%) 08/05/22 Pfizer in advanced talks to buy Global Blood for about $5B, WSJ reports 08/05/22 Pfizer in talks to buy Global Blood Therapeutics for about $5B, WSJ says 07/18/22 GSK CEO says split will help deal with 'perennial underperformance,' FT reports 06/28/22 FDA panel recommends omicron update for COVID vaccine boosters, CNBC says GSK GSK plc $34.55 / -1.495 (-4.15%) 08/11/22 GSK, Sanofi weakness related to Zantac litigation worries, Bloomberg reports 07/18/22 GSK CEO says split will help deal with 'perennial underperformance,' FT reports 06/27/22 GSK's Haleon chooses Citi, UBS as spinoff brokers, Bloomberg says 06/27/22 GSK's Haleon chooses Citi, UBS as spinoff brokers, Bloomberg says HLN PFE GSK HLN Haleon $6.35 / -0.345 (-5.15%) 08/11/22 Renewed Zantac litigation concerns sinking these big-cap drugmakers 08/11/22 What You Missed On Wall Street This Morning 07/29/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 07/18/22 What You Missed On Wall Street This Morning PFE Pfizer $49.55 / -0.55 (-1.10%) 08/11/22 Renewed Zantac litigation concerns sinking these big-cap drugmakers 08/08/22 What You Missed On Wall Street On Monday 08/08/22 What You Missed On Wall Street This Morning 08/08/22 Fly Intel: Pre-market Movers GSK GSK plc $34.55 / -1.495 (-4.15%) 08/11/22 What You Missed On Wall Street On Thursday 08/11/22 Renewed Zantac litigation concerns sinking these big-cap drugmakers 08/11/22 What You Missed On Wall Street This Morning 08/09/22 What You Missed On Wall Street On Tuesday 09/10/22 ESMO Congress 2022 HLN PFE GSK HLN Haleon $6.35 / -0.345 (-5.15%) 07/27/22 new option listings and one option delisting on July 27th PFE Pfizer $49.55 / -0.55 (-1.10%) 08/11/22 Pfizer call volume above normal and directionally bullish 07/28/22 Unusually active option classes on open July 28th 06/30/22 Early notable gainers among liquid option names on June 30th 05/20/22 Early notable gainers among liquid option names on May 20th GSK GSK plc $34.55 / -1.495 (-4.15%) 09:40 Today Unusually active option classes on open August 15th 08/12/22 Unusually active option classes on open August 12th 08/11/22 GSK plc (ADR) call volume above normal and directionally bullish 08/10/22 GSK plc (ADR) call volume above normal and directionally bullish
Recommendations	Russel Metals price target raised to C$42 from C$39 at RBC Capital » 12:01 08/15/22 08/15 12:01 08/15/22 12:01 RUSMF Russel Metals $23.20 / +0.67 (+2.97%) RBC Capital analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research RUSMF Russel Metals $23.20 / +0.67 (+2.97%) 11:09 Today Scotiabank Russel Metals price target lowered to C$37.50 from C$38.50 at Scotiabank 08/12/22 BMO Capital Russel Metals price target lowered to C$32 from C$36 at BMO Capital 08/12/22 Stifel Russel Metals price target raised to C$40 from C$34 at Stifel 07/18/22 RBC Capital Russel Metals price target lowered to C$39 from C$45 at RBC Capital
Conference/Events	Cantor Fitzgerald equity derivative analyst has analyst/industry conference call » 12:01 08/15/22 08/15 12:01 08/15/22 12:01 Equity Derivatives and… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial
Recommendations	Northland Power price target raised to C$48 from C$46 at RBC Capital » 12:01 08/15/22 08/15 12:01 08/15/22 12:01 NPIFF Northland Power $35.76 / +1.22 (+3.53%) RBC Capital analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research NPIFF Northland Power $35.76 / +1.22 (+3.53%) 07/11/22 Northland Power signs corporate power purchase agreement 05/17/22 Northland Power announces amendment to diversity policy 05/09/22 BNP Paribas, Northland Power partner with Export Development Canada 04/27/22 Northland Power launches refreshed brand NPIFF Northland Power $35.76 / +1.22 (+3.53%) 11:30 Today National Bank Northland Power price target raised to C$49 from C$47 at National Bank 11:04 Today Scotiabank Northland Power price target raised to C$51 from C$46.25 at Scotiabank 10:53 Today TD Securities Northland Power price target raised to C$55 from C$47 at TD Securities 08/12/22 BMO Capital Northland Power price target raised to C$50 from C$44 at BMO Capital
Recommendations	MDA Ltd price target lowered to C$13 from C$15 at RBC Capital » 12:01 08/15/22 08/15 12:01 08/15/22 12:01 MDALF MDA Ltd / + RBC Capital analyst Ken… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research MDALF MDA Ltd / + 07/07/22 MDA appoints Johnson as Vice President of RSO MDALF MDA Ltd / + 05/12/22 BMO Capital MDA Ltd price target lowered to C$11 from C$13 at BMO Capital 05/12/22 Canaccord MDA Ltd price target lowered to C$15 from C$20 at Canaccord 03/18/22 Canaccord MDA Ltd price target lowered to C$20 from C$21 at Canaccord 03/18/22 RBC Capital MDA Ltd price target raised to C$15 from C$13 at RBC Capital
Recommendations	H&R REIT price target raised to C$15.75 from C$15 at RBC Capital » 12:00 08/15/22 08/15 12:00 08/15/22 12:00 HRUFF H&R REIT $10.86 / +0.21 (+1.97%) RBC Capital analyst Matt… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research HRUFF H&R REIT $10.86 / +0.21 (+1.97%) 11:37 Today National Bank H&R REIT price target raised to C$16.50 from C$15.25 at National Bank 07/20/22 National Bank H&R REIT price target lowered to C$15.25 from C$18.50 at National Bank 05/18/22 Scotiabank H&R REIT price target raised to C$16.50 from C$15.25 at Scotiabank 05/16/22 BMO Capital H&R REIT price target raised to C$18 from C$16 at BMO Capital
Hot Stocks	Redwire falls -9.9% » 12:00 08/15/22 08/15 12:00 08/15/22 12:00 RDW Redwire $3.57 / -0.35 (-8.93%) Redwire is down -9.9%, or… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options RDW Redwire $3.57 / -0.35 (-8.93%) 07/01/22 Redwire added to broad-market Russell 3000 Index 06/07/22 Redwire awarded contract to manufacture link-16 antennas 06/01/22 Redwire CFO Bill Read to transition out of role, Jonathan Baliff to succeed 05/03/22 Redwire names Al Tadros Chief Technology Officer RDW Redwire $3.57 / -0.35 (-8.93%) 09/28/21 Fly Intel: Top five analyst initiations 09/28/21 Jefferies Redwire initiated with a Buy at Jefferies RDW Redwire $3.57 / -0.35 (-8.93%) 05/12/22 Redwire reports Q1 EPS (28c) vs. (21c) last year 03/31/22 Redwire sees FY22 revenue $165M-$195M vs. $96.8M in FY21 03/31/22 Redwire reports Q4 EPS (55c) vs. (6c) last year RDW Redwire $3.57 / -0.35 (-8.93%) 04/01/22 What You Missed On Wall Street On Friday 04/01/22 What You Missed On Wall Street This Morning 03/31/22 Fly Intel: After-Hours Movers RDW Redwire $3.57 / -0.35 (-8.93%) 03/23/22 Largest borrow rate increases among liquid names 03/15/22 Largest borrow rate increases among liquid names 03/14/22 Largest borrow rate increases among liquid names 03/11/22 Largest borrow rate increases among liquid names
Hot Stocks	Turquoise Hill falls -10.4% » 12:00 08/15/22 08/15 12:00 08/15/22 12:00 TRQ Turquoise Hill $23.56 / -2.68 (-10.21%) Turquoise Hill is down… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly TRQ Turquoise Hill $23.56 / -2.68 (-10.21%) 10:00 Today Turquoise Hill falls -14.1% 09:47 Today Turquoise Hill falls -17.0% 09:19 Today Turquoise Hill down 17% after terminating review to be bought by Rio Tinto 06:37 Today Rio Tinto reiterates proposal for acquisition of Turquoise Hill TRQ Turquoise Hill $23.56 / -2.68 (-10.21%) 08/08/22 Canaccord Turquoise Hill price target lowered to C$42 from C$44 at Canaccord 08/08/22 TD Securities Turquoise Hill price target lowered to C$38 from C$40 at TD Securities 08/08/22 Canaccord Turquoise Hill price target lowered to C$42 from C$44 at Canaccord 07/14/22 Canaccord Turquoise Hill price target lowered to C$44 from C$45 at Canaccord TRQ Turquoise Hill $23.56 / -2.68 (-10.21%) 08/04/22 Turquoise Hill backs FY22 copper production guidance 08/04/22 Turquoise Hill reports Q2 EPS 51c, consensus 36c 05/10/22 Turquoise Hill reports Q1 EPS $1.37, consensus 28c TRQ Turquoise Hill $23.56 / -2.68 (-10.21%) 04/19/22 Fly Intel: After-Hours Movers 03/14/22 What You Missed On Wall Street On Monday 03/14/22 What You Missed On Wall Street This Morning

Hot Stocks	SmartRent falls -13.2% » 12:00 08/15/22 08/15 12:00 08/15/22 12:00 SMRT SmartRent $3.32 / -0.495 (-12.99%) SmartRent is down -13.2%,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly SMRT SmartRent $3.32 / -0.495 (-12.99%) 08/12/22 SmartRent falls -32.7% 08/12/22 SmartRent falls -26.6% 08/12/22 SmartRent falls -19.5% 08/11/22 SmartRent falls 28% to $4.02 after Q2 earnings miss and guidance cut SMRT SmartRent $3.32 / -0.495 (-12.99%) 08/12/22 Cantor Fitzgerald SmartRent price target lowered to $5.25 from $6.00 at Cantor Fitzgerald 07/22/22 Cantor Fitzgerald SmartRent assumed with an Overweight at Cantor Fitzgerald 07/19/22 Keefe Bruyette Bain Capital sold 5% of stake in SmartRent, says Keefe Bruyette 05/25/22 Compass Point Compass Point starts SmartRent at Buy, sees 'exponential growth potential' SMRT SmartRent $3.32 / -0.495 (-12.99%) 08/11/22 SmartRent cuts FY22 revenue view to $155M-$180M from $220M-$250M 08/11/22 SmartRent sees Q3 revenue $43M-$47M, consensus $75.4M 08/11/22 SmartRent reports Q2 EPS (13c), consensus (11c) 05/11/22 SmartRent sees FY22 revenue $220M-$250M, consensus $238.1M SMRT SmartRent $3.32 / -0.495 (-12.99%) 08/12/22 What You Missed On Wall Street On Friday 08/12/22 What You Missed On Wall Street This Morning 08/11/22 Fly Intel: After-Hours Movers 05/11/22 Fly Intel: After-Hours Movers
Hot Stocks	Enhabit rises 16.0% » 12:00 08/15/22 08/15 12:00 08/15/22 12:00 EHAB Enhabit $16.08 / +2.27 (+16.44%) Enhabit is up 16.0%, or… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly EHAB Enhabit $16.08 / +2.27 (+16.44%) 08/02/22 Enhabit falls -13.9% 08/02/22 Enhabit falls -13.3% 07/05/22 Enhabit to replace Loyalty Ventures in S&P 600 at open on 7/5 07/01/22 Encompass Health completes spin off of Enhabit EHAB Enhabit $16.08 / +2.27 (+16.44%) 08/08/22 Truist Encompass Health price target lowered to $65 from $75 at Truist 07/13/22 BofA BofA starts Enhabit at Underperform on Medicare rate risks 07/13/22 BofA Enhabit initiated with an Underperform at BofA EHAB Enhabit $16.08 / +2.27 (+16.44%) 08/01/22 Enhabit cuts FY22 EPS view to $1.47-$1.75 from $1.64-$2.01 08/01/22 Enhabit reports Q2 EPS 47c vs. 71c last year EHAB Enhabit $16.08 / +2.27 (+16.44%) 08/01/22 Fly Intel: After-Hours Movers 07/01/22 What You Missed On Wall Street On Friday 07/01/22 What You Missed On Wall Street This Morning
Hot Stocks	Blue Apron rises 20.7% » 12:00 08/15/22 08/15 12:00 08/15/22 12:00 APRN Blue Apron $4.60 / +0.795 (+20.89%) Blue Apron is up 20.7%,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options APRN Blue Apron $4.60 / +0.795 (+20.89%) 09:47 Today Blue Apron rises 11.5% 08/11/22 Blue Apron introduces new Tailgating Box 'in time for football season' 08/08/22 Blue Apron rises 17.8% 08/08/22 Blue Apron sees a route to revenue acceleration in the second half APRN Blue Apron $4.60 / +0.795 (+20.89%) 08/10/22 Lake Street Blue Apron initiated with a Buy at Lake Street 07/20/22 Benchmark Benchmark starts Blue Apron at Buy with turnaround not getting credit 07/20/22 Benchmark Blue Apron initiated with a Buy at Benchmark 05/10/22 Canaccord Blue Apron price target lowered to $10 from $12 at Canaccord APRN Blue Apron $4.60 / +0.795 (+20.89%) 08/08/22 Blue Apron cuts FY22 revenue growth view to 7%-13% vs. mid-teens 08/08/22 Blue Apron reports Q2 EPS (68c) vs. (98c) a year ago 05/10/22 Blue Apron targets revenue of $700M-plus in 2024 05/09/22 Blue Apron sees FY revenue growth in mid teens, one est. $532.3M APRN Blue Apron $4.60 / +0.795 (+20.89%) 05/10/22 Blue Apron shares going to $10 unless management 'sociopaths,' Citrons says APRN Blue Apron $4.60 / +0.795 (+20.89%) 08/12/22 Short Report: Bed Bath Beyond shorts nudge higher as stock soars 08/10/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/04/22 Short Report: GameStop short position reaches 15-month high 06/01/22 Fly Intel: After-Hours Movers 08/17/22 August Virtual Micro Cap Conference APRN Blue Apron $4.60 / +0.795 (+20.89%) 09:40 Today Unusually active option classes on open August 15th 07/07/22 Largest borrow rate increases among liquid names 06/24/22 Largest borrow rate increases among liquid names 06/23/22 Largest borrow rate increases among liquid names
Hot Stocks	Revlon rises 22.6% » 12:00 08/15/22 08/15 12:00 08/15/22 12:00 REV Revlon $8.05 / +1.48 (+22.53%) Revlon is up 22.6%, or… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Earnings Periodicals On The Fly Options REV Revlon $8.05 / +1.48 (+22.53%) 08/09/22 Revlon CFO Victoria Dolan to retire, Matt Kvarda to become interim CFO 07/20/22 Origin Materials, Revlon enter carbon negative material joint initiative 07/01/22 Revlon rises 14.9% 07/01/22 Revlon rises 13.0% REV Revlon $8.05 / +1.48 (+22.53%) 05/04/22 Revlon reports Q1 EPS ($1.14) vs. ($1.55) last year 03/03/22 Revlon reports Q4 EPS 18c, one estimate 6c REV Revlon $8.05 / +1.48 (+22.53%) 06/21/22 Revlon's bankruptcy may be impacted by Citi's $900M error, FT reports 06/17/22 Indian conglomerate Reliance is considering to buy out Revlon, Reuters reports 06/10/22 Revlon preparing Chapter 11 filing as soon as next week, WSJ reports 06/10/22 Revlon nears Chapter 11 filing, WSJ reports, citing sources REV Revlon $8.05 / +1.48 (+22.53%) 08/12/22 Short Report: Bed Bath Beyond shorts nudge higher as stock soars 07/23/22 Short Report: Revlon shorts recede, stock retreats as buyout news fades 07/16/22 Short Report: Canoo shorts going along for the ride 06/18/22 Short Report: Short interest in crypto names spikes as bears pounce on bitcoin REV Revlon $8.05 / +1.48 (+22.53%) 08/02/22 Revlon call volume above normal and directionally bullish 08/02/22 Unusually active option classes on open August 2nd 08/01/22 Revlon call volume above normal and directionally bullish 07/29/22 Largest borrow rate increases among liquid names
Recommendations	Granite Real Estate price target raised to C$100 from C$99 at RBC Capital » 11:59 08/15/22 08/15 11:59 08/15/22 11:59 GRP Granite Real Estate $38.91 / + (+0.00%) RBC Capital analyst Pammi… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research GRP Granite Real Estate $38.91 / + (+0.00%) 11:37 Today National Bank Granite Real Estate price target raised to C$90 from C$85 at National Bank 07/20/22 National Bank Granite Real Estate price target lowered to C$85 from C$115 at National Bank 05/16/22 Desjardins Granite Real Estate price target lowered to C$104 from C$111 at Desjardins 04/29/22 Scotiabank Granite Real Estate price target raised to C$110 from C$109 at Scotiabank
Recommendations	Akouos files IND for AK-OTOF, says Piper Sandler » 11:59 08/15/22 08/15 11:59 08/15/22 11:59 AKUS Akouos $3.43 / +0.35 (+11.36%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly AKUS Akouos $3.43 / +0.35 (+11.36%) 07:04 Today Akouos expects cash to fund operations beyond next eighteen months 05/19/22 Akouos presents nonclinical data on AK-OTOF, microRNA target sites 03/10/22 Akouos appoints Aaron Tward as CSO AKUS Akouos $3.43 / +0.35 (+11.36%) 05/17/22 Piper Sandler Akouos price target lowered to $18 from $40 at Piper Sandler AKUS Akouos $3.43 / +0.35 (+11.36%) 07:04 Today Akouos reports Q2 EPS (58c), consensus (76c) 05/12/22 Akouos reports Q1 EPS (78c), consensus (73c) 03/29/22 Akouos reports Q4 EPS (72c), consensus (66c) AKUS Akouos $3.43 / +0.35 (+11.36%) 08:56 Today Fly Intel: Pre-market Movers
Recommendations	Exchange Income price target raised to C$63 from C$62 at RBC Capital » 11:59 08/15/22 08/15 11:59 08/15/22 11:59 EIFZF Exchange Income $38.22 / +0.88 (+2.36%) RBC Capital analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research EIFZF Exchange Income $38.22 / +0.88 (+2.36%) 11:36 Today National Bank Exchange Income price target raised to C$61 from C$59 at National Bank 11:01 Today Scotiabank Exchange Income price target raised to C$60 from C$56 at Scotiabank 10:52 Today TD Securities Exchange Income price target raised to C$67 from C$59 at TD Securities 05/17/22 RBC Capital Exchange Income price target raised to C$62 from C$52 at RBC Capital
Recommendations	ECN Capital price target raised to C$8 from C$7.50 at RBC Capital » 11:57 08/15/22 08/15 11:57 08/15/22 11:57 ECNCF ECN Capital $5.57 / +0.384 (+7.40%) RBC Capital analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research ECNCF ECN Capital $5.57 / +0.384 (+7.40%) 08/12/22 BMO Capital ECN Capital price target raised to C$8 from C$7 at BMO Capital 08/12/22 Raymond James ECN Capital price target raised to C$8 from C$7 at Raymond James 08/12/22 National Bank ECN Capital price target raised to C$8.50 from C$8 at National Bank 08/09/22 TD Securities ECN Capital price target raised to C$8.50 from C$8 at TD Securities
Recommendations	Dialogue Health price target lowered to C$6 from C$7 at RBC Capital » 11:57 08/15/22 08/15 11:57 08/15/22 11:57 DLHTF Dialogue Health $2.30 / + (+0.00%) RBC Capital analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research DLHTF Dialogue Health $2.30 / + (+0.00%) 08/12/22 Scotiabank Dialogue Health price target lowered to C$8 from C$8.50 at Scotiabank 08/12/22 TD Securities Dialogue Health price target lowered to C$4.50 from C$5.50 at TD Securities 08/09/22 National Bank Dialogue Health price target lowered to C$8.50 from C$11.50 at National Bank
Recommendations	Chemtrade Logistics price target raised to C$10 from C$9 at RBC Capital » 11:56 08/15/22 08/15 11:56 08/15/22 11:56 CGIFF Chemtrade Logistics $7.17 / +0.06 (+0.84%) RBC Capital analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research CGIFF Chemtrade Logistics $7.17 / +0.06 (+0.84%) 11:34 Today National Bank Chemtrade Logistics price target raised to C$11 from C$9.25 at National Bank 11:15 Today Desjardins Chemtrade Logistics price target raised to C$11.75 from C$11 at Desjardins 08/12/22 BMO Capital Chemtrade Logistics price target raised to C$9 from C$8 at BMO Capital 08/12/22 Scotiabank Chemtrade Logistics price target raised to C$10.50 from C$10.25 at Scotiabank

Hot Stocks	Novartis' treatment of Malaria granted FDA orphan designation » 11:56 08/15/22 08/15 11:56 08/15/22 11:56 NVS Novartis $85.05 / -0.63 (-0.74%) Novartis… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options NVS Novartis $85.05 / -0.63 (-0.74%) 05:13 Today Novartis announces CANOPY-A trial did not meet primary endpoint 08/11/22 FDA grants regular approval to Novartis' capmatinib for metastatic NSCLC 08/08/22 Chimerix appoints Jordan as VP, Regulatory Affairs 07/28/22 Bausch Health to appeal expected court decision on certain Xifaxan patents NVS Novartis $85.05 / -0.63 (-0.74%) 08/05/22 Truist Global Blood could complement any oncology franchise, says Truist 08/04/22 Truist Truist sees Novartis, Vertex as logical suitors for Global Blood 07/20/22 JPMorgan Novartis price target raised to CHF 81 from CHF 80 at JPMorgan 07/20/22 Piper Sandler Piper adjusts Ionis' Spinraza royalties estimate following Biogen report NVS Novartis $85.05 / -0.63 (-0.74%) 07/19/22 Novartis reports Q2 core EPS $1.56 vs. $1.66 a year ago 04/26/22 Novartis sees 2022 core operating income to grow mid single digit 04/26/22 Novartis reports Q1 core EPS $1.46, consensus $1.46 NVS Novartis $85.05 / -0.63 (-0.74%) 08/11/22 Two died from acute liver failure after use of Novartis' Zolgensma, STAT says 06/30/22 Novartis favoring spinoff of $25B Sandoz unit, Bloomberg reports 06/30/22 Novartis said to lean toward Sandoz spinoff over sale, Bloomberg says 06/28/22 Novartis to cut up to 8,000 jobs, or 7% of workforce, in restructuring NVS Novartis $85.05 / -0.63 (-0.74%) 08/12/22 What You Missed On Wall Street This Morning 06/30/22 What You Missed On Wall Street On Thursday 06/30/22 What You Missed On Wall Street This Morning 06/28/22 What You Missed On Wall Street On Tuesday 09/10/22 ESMO Congress 2022 09/19/22 Novartis NVS Novartis $85.05 / -0.63 (-0.74%) 08/09/22 Largest borrow rate increases among liquid names
Recommendations	AG Growth International price target raised to C$55 from C$50 at RBC Capital » 11:56 08/15/22 08/15 11:56 08/15/22 11:56 AGGZF AG Growth International $30.82 / +1.01285 (+3.40%) RBC Capital analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research AGGZF AG Growth International $30.82 / +1.01285 (+3.40%) 11:11 Today Desjardins AG Growth International price target raised to C$53 from C$48 at Desjardins 08/12/22 Scotiabank AG Growth International price target raised to C$55 from C$52 at Scotiabank 04/20/22 Scotiabank AG Growth International price target raised to C$52 from C$50 at Scotiabank 03/17/22 RBC Capital AG Growth International price target raised to C$50 from C$45 at RBC Capital
Hot Stocks	Take-Two's Private Division to publish Middle-Earth game » 11:54 08/15/22 08/15 11:54 08/15/22 11:54 TTWO Take-Two $127.36 / +4.22 (+3.43%) Take-Two's Private… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options TTWO Take-Two $127.36 / +4.22 (+3.43%) 09:06 Today Take-Two unit Private Division in publishing pact with Weta Workshop 08/09/22 Take-Two CEO: We're very confident in our upcoming titles 08/08/22 Take-Two delays 'Marvel's Midnight Suns' to fiscal 2023 08/02/22 U.S. video game consumer spending fell 13% y/y in Q2, says NPD TTWO Take-Two $127.36 / +4.22 (+3.43%) 08/10/22 DZ Bank Take-Two downgraded to Hold from Buy at DZ Bank 08/09/22 BofA BofA downgrades Take-Two, says risk/reward less appealing after Zynga deal 08/09/22 BofA Take-Two downgraded to Neutral from Buy at BofA 08/09/22 Oppenheimer Take-Two price target lowered to $180 from $190 at Oppenheimer TTWO Take-Two $127.36 / +4.22 (+3.43%) 08/08/22 Take-Two sees FY23 revenue $5.73B-$5.8B, consensus $6.32B 08/08/22 Take-Two reports Q2 EPS (76c) vs. $1.30 last year 05/16/22 Take-Two sees Q1 GAAP EPS 80c-90c, consensus 90c 05/16/22 Take-Two sees FY23 GAAP EPS $1.90-$2.15, consensus $5.99 TTWO Take-Two $127.36 / +4.22 (+3.43%) 07/21/22 Europe game sales rose 13.5% year-over-year in 1H22, Gamesindustry.biz says 07/11/22 Rockstar shelved plans for 'Red Dead 2' next-gen upgrade, VGC reports 07/05/22 Take-Two's Rockstar halts development of 'Red Dead,' 'GTA4' remakes, Kotaku says 04/14/22 'Elden Ring' top-selling game in Europe in March, Gamesindustry.biz says TTWO Take-Two $127.36 / +4.22 (+3.43%) 08/09/22 What You Missed This Week in Video Games 08/02/22 What You Missed This Week in Video Games 07/26/22 What You Missed This Week in Video Games 07/19/22 What You Missed This Week in Video Games 09/08/22 Consumer/Media/Entertainment Conference 09/16/22 Take-Two Interactive Software Inc. TTWO Take-Two $127.36 / +4.22 (+3.43%) 06/07/22 Early notable gainers among liquid option names on June 7th 05/25/22 Notable open interest changes for May 25th 05/17/22 Early notable gainers among liquid option names on May 17th 04/22/22 TakeTwo Interactive Software call volume above normal and directionally bullish
Hot Stocks	Taseko Mines reports EPA issues draft permit for Florence Copper Project » 11:54 08/15/22 08/15 11:54 08/15/22 11:54 TGB Taseko Mines $1.20 / +0.11 (+10.09%) Taseko Mines announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Options TGB Taseko Mines $1.20 / +0.11 (+10.09%) 07/07/22 Taseko Mines updates status of copper price protection program 03/30/22 Taseko Mines announces 40% increase in Gibraltal Mine reserves TGB Taseko Mines $1.20 / +0.11 (+10.09%) 08/10/22 Scotiabank Taseko Mines price target lowered to C$1.75 from C$2 at Scotiabank 08/10/22 TD Securities Taseko Mines price target lowered to C$2.25 from C$2.50 at TD Securities 08/09/22 BMO Capital Taseko Mines price target lowered to C$2.50 from C$2.75 at BMO Capital 07/19/22 Stifel Taseko Mines price target lowered to C$2.50 from C$3.40 at Stifel TGB Taseko Mines $1.20 / +0.11 (+10.09%) 02/22/22 Taseko Mines options imply 11.3% move in share price post-earnings
Recommendations	Viridian Therapeutics price target raised to $50 from $40 at Evercore ISI » 11:51 08/15/22 08/15 11:51 08/15/22 11:51 VRDN Viridian Therapeutics $23.74 / +8.855 (+59.51%) Evercore ISI analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events VRDN Viridian Therapeutics $23.74 / +8.855 (+59.51%) 09:42 Today Viridian Therapeutics trading resumes 09:37 Today Viridian Therapeutics trading halted, volatility trading pause 07:07 Today Viridian Therapeutics- VRDN-001 shows efficacy in Phase 1/2 trial for TED 08/05/22 Viridian Therapeutics announces inducement grants under Nasdaq listing rule VRDN Viridian Therapeutics $23.74 / +8.855 (+59.51%) 06/23/22 B. Riley B. Riley starts Viridian Therapeutics at Buy with $25 price target 06/23/22 B. Riley Viridian Therapeutics initiated with a Buy at B. Riley 11/18/21 SVB Leerink Viridian Therapeutics initiated with an Outperform at SVB Leerink 11/05/21 JMP Securities Viridian Therapeutics price target lowered to $36 from $44 at JMP Securities VRDN Viridian Therapeutics $23.74 / +8.855 (+59.51%) 07:17 Today Viridian Therapeutics reports Q2 EPS ($1.06), consensus (90c) 05/12/22 Viridian Therapeutics reports Q1 EPS (98c), consensus ($1.08) 03/10/22 Viridian Therapeutics reports Q4 EPS ($1.32), consensus (90c) 21 Sep VRDN Viridian Therapeutics $23.74 / +8.855 (+59.51%) 08:56 Today Fly Intel: Pre-market Movers 08:00 Today Viridian Therapeutics - VRDN

Events

Earnings calls, analyst events, roadshows and more

HCDI
Today at 12:30

Harbor Custom Development - HCDI Conference Calls
MCHP
Today at 13:00

Microchip - MCHP Conference Calls
BDC
Today at 13:00

Belden - BDC Conference Calls
DGX
Today at 13:00

Quest Diagnostics - DGX Conference Calls
REKR
Today at 13:00

Rekor Systems Inc Firm Sponsored Meetings

6721 Columbia Gateway Dr Suite 400, Columbia, MD
Today at 13:00

Natural Resources Industry Meetings
EBR
Today at 13:30

Eletrobras - EBR Conference Calls
DXYN
Today at 14:00

Dixie Group - DXYN Conference Calls
Today at 16:00

Treasury Int'l Capital: Net L-T Securities Transactions: June 2022 Government Event
TTOO
Today at 16:30

T2 Biosystems - TTOO Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	LUCY X LUCY Innovative Eyewear IPO Managers: Maxim Priced at: $7.50 980K Shares
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	GRFX X GRFX Graphex Group Secondary Managers: EF Hutton $2.00-3.00 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	No deals
Wed	No deals
Thurs	GFRX X GFRX Graphex Group Secondary Managers: EF Hutton $2.00-3.00 8M Shares
Fri	No deals

View All Syndicate Announcements »

Moleculin Biotech receives IND clearance for Phase 1 study of glioma candidate

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access